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Background: Parkinson’s disease (PD), the second most common neurodegenerative disease, is characterized by
loss of dopaminergic neurons in the substantia nigra. The clinical manifestations of PD encompass a variety of
motor and non-motor symptoms. Mutations in the F-box protein 7 gene (FBXO7) have been identified to cause
Parkinsonian-pyramidal syndrome, an autosomal recessive form of Parkinsonism. The F-box protein 42 gene
(FBXO42), a paralog of the FBXO7 gene, is involved in the ubiquitin-proteasome system that may play a role in the
pathogenesis of PD.
Methods: To determine whether the FBXO42 gene is associated with PD, we performed a systematic genetic
analysis of the FBXO42 gene in 316 PD patients and 295 gender-, age-, and ethnicity-matched normal controls.
Results: We identified a novel variant c.1407T>C (p.S469S) and three known single nucleotide variants, including
rs2273311, rs12069239 and rs35196193 in the FBXO42 gene in PD patient group. None of the three known variants
displayed statistically significant difference in either genotypic or allelic distributions between patient and control
groups (all P > 0.05). Haplotype analysis showed that a common haplotype (G-C-G) for the three single nucleotide
variants conferred a 1.69-fold increased risk for PD (P = 0.008 after Bonferroni correction, OR = 1.69, 95% CI = 1.06-2.71).
Conclusions: Our findings suggest that a haplotype of the FBXO42 gene might be associated with a higher
susceptibility to PD.
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Parkinson’s disease (PD) is the second most common
neurodegenerative disorder after Alzheimer’s disease.
The prevalence of PD increases with age, from about 1%
among individuals over age 65 to about 4% in those over
age 85 [1]. It is characterized clinically by motor mani-
festations, including bradykinesia, resting tremor, rigid-
ity and postural instability [2]. However, increasing
evidence indicates that non-motor manifestations are
common during the course of the disease, and become
particularly disabling in advanced stages of PD [3].
Though environmental factors have been identified to
increase PD risk, accumulating evidence suggests that
genetic predisposition contributes to the pathogenesis
of the disorder as well [4]. In the last two decades, at* Correspondence: hdeng008@yahoo.com
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reproduction in any medium, provided the orleast 18 chromosomal loci (PARK1-18) have been assigned
to PD through classic linkage analysis or genome-wide
association studies [5], and eight genes (SNCA, LRRK2,
Parkin, PINK1, DJ-1, ATP13A2, VPS35 and EIF4G1)
have been linked to autosomal PD [6]. Mutations in
genes responsible for monogenic forms of PD have also
been identified in some sporadic cases of PD. These
findings support the hypothesis that genetic factors may
be implicated in both familial and sporadic PD [7].
Though a number of susceptibility variants for sporadic
PD have been identified by genome-wide association
studies, the association between some of the variants
and PD is unable to be replicated due to a variety of
factors, including racial differences, insufficient power,
population stratification and differences in sample size
[8]. The genetic causes in majority of sporadic cases of
PD remain unknown, suggesting that other genetic vari-
ations may also contribute to the development of the
disease.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Gao et al. BMC Neurology 2013, 13:125 Page 2 of 5
http://www.biomedcentral.com/1471-2377/13/125Mutations in the F-box protein 7 gene (FBXO7), encod-
ing a protein of the F-box protein family, have been identi-
fied as a cause for Parkinsonian-pyramidal syndrome, an
autosomal recessive neurodegenerative disease with severe
levodopa-responsive Parkinsonism, and additional pyram-
idal signs [9]. Recent evidence from genetics and animal
model has suggested a possible role of the FBXO7 gene in
PD [10,11].
The FBXO42 gene, a paralog of the FBXO7 gene, en-
codes another important member of the F-box protein
family. It is known that paralogs often retain similar func-
tion [12] and may play similar roles in the development of
a certain disorder [13]. Additionally, FBXO42 is involved
in protein degradation via the ubiquitin-proteasome
system that is proposed as a potential mechanism for
PD [14-16]. The aim of the present study is to deter-
mine whether the FBXO42 gene is associated with PD
in Chinese Han population.
Methods
Patients and controls
Three hundred and sixteen unrelated Chinese Han
patients with PD (Male/female = 160/156; age years
61.68 ± 11.20; onset age years 58.53 ± 12.37), and 295
gender-, age- and ethnicity-matched healthy controls
(Male/female = 150/145; age years 62.91 ± 11.45) with-
out any family history of neurological disorders were
recruited for this study. All patients were tested at
Department of Neurology, the Third Xiangya Hospital
of Central South University and diagnosed according
to accepted diagnostic criteria [2]. The control subjects
were recruited from the Third Xiangya Hospital Medical
Center and a standard clinical neurological examination
was performed on all control subjects to exclude a diagno-
sis of possible idiopathic PD. There was no statistically sig-
nificant difference in age or gender between patient and
control groups (P > 0.05, using χ2 test for gender and the
Student’s t-test for age). The protocol of this study was ap-
proved by the Ethics Committee of the Third Xiangya
Hospital of Central South University and all the individ-
uals signed informed consent.
Genetic analysis
Genomic DNA (gDNA) was isolated from lymphocytes
using standard phenol-chloroform method. Polymerase
chain reaction (PCR) was carried out in a reaction volume
of 25 μl, containing 100 ng of gDNA and 10 pmol of each
primer, in the 9700 Thermal Cycler System (Applied
Biosystems Inc, Foster City, CA). The PCR consisted of 35
cycles of denaturation at 95°C for 40 s, annealing at 58°C
for 35 s, and extension at 72°C for 40 s, and a final exten-
sion step at 72°C for 5 minutes. PCR amplified all coding
region and intron/exon boundaries of the FBXO42 gene
by using 14 primer pairs (Additional file 1: Table S1,available online) and a two-step screening strategy was
performed in this study. In the first step, mutation in the
coding region and flanking sequence of the FBXO42 gene
was screened by previously described method in 151 PD
patients (Male/female = 77/74; age years 61.84 ± 12.75;
onset age years 58.14 ± 14.38) [17]. In the second step, the
risk of the variants was evaluated between enlarged PD
group (316 patients including first 151 patients) and
gender-, age- and ethnicity-matched normal controls (295
individuals) to increase statistical sensitivity. A sequenced
normal control and a negative control (without DNA
sample) were set in every experiment. The abnormal
single strand conformation polymorphism bands of
PCR products were sequenced using ABI 3500 genetic
analyzer (Applied Biosystems Inc, Foster City, CA).
Statistical analysis
The power of the study was calculated using Power and
Sample Size Program [18]. The power to detect associ-
ation with the disorder in 316 cases and 295 controls was
estimated to be 83.7%, 80.2%, and 81.0%, with a relative
risk of ≥1.6 at a significance level of 0.05 when testing var-
iants with the minor allele frequencies of 0.409, 0.298, and
0.039, respectively. All the variants were tested for devi-
ation from Hardy–Weinberg equilibrium (HWE). Associ-
ation analysis was carried out using chi-squared test or
fisher’s exact test to assess genotypic or allelic association
between PD and each of the variants. Haplotype analysis,
a molecular genetic testing to identify a set of closely
linked segments of DNA that used in linkage analysis or
when a given trait is in linkage disquilibrium with a
marker or set of markers, was also performed to estimate
the association of a haplotype with PD. Haplotypes with
a frequency less than 0.03 were excluded in the analysis
and Bonferroni correction was applied for all significant
P values. Statistical analysis was performed using
PASW18.0 (SPSS Inc., Chicago, IL, USA) and PLINK 1.07
(http://pngu.mgh.harvard.edu/~purcell/plink/). A value
(P < 0.05, two-tailed) was considered to be significant.
Results
A novel variant c.1407T>C was identified in a 78-year-old
male patient with sporadic PD and was absent in all
controls (Additional file 2: Figure S1, available online).
The single nucleotide variation does not change amino acid
(p.S469S) or splicing (predicted by http://www.fruitfly.org/
seq_tools/splice.html). Three known single nucleotide
variants, including c.15G>A (p.S5S, rs2273311), c.1411C>G
(p.P471A, rs12069239), and c.1525G>A (p.A509T, rs35196193)
were found in our PD cohort. None of the three known
variants showed deviations from HWE in control group,
or patient group, or the cohort as a whole. None of the
three known variants displayed statistically significant dif-
ference in either genotypic or allelic distributions between
Table 1 Genotypic and allelic distributions of FBXO42 variants in PD patients and control subjects
Variants Amino acid change Genotype/Allele N (%) P-value (χ2) P-value (χ2) OR (95% CI)
Cases Controls
rs2273311 p.S5S GG 31 (9.81) 26 (8.81)
GA 138 (43.67) 126 (42.71)
AA 147 (46.52) 143 (48.48) 0.85 (0.32)
G 200 (31.65) 178 (30.17)
A 432 (68.35) 412 (69.83) 0.58 (0.31) 1.07 (0.84-1.37)
rs12069239 p.P471A CC 219 (69.30) 191 (64.75)
CG 92 (29.11) 93 (31.53)
GG 5 (1.59) 11 (3.72) 0.18 (3.45)
C 530 (83.86) 475 (81.51)
G 102 (16.14) 115 (19.49) 0.13 (2.35) 1.26 (0.94-1.69)
rs35196193 p.A509T GG 294 (93.04) 268 (90.85)
GA 20 (6.33) 27 (9.15)
AA 2 (0.63) 0 (0.00) 0.16 (3.15)
G 608 (96.20) 563 (95.42)
A 24 (3.80) 27 (4.58) 0.50 (0.46) 1.22 (0.69-2.13)
OR, Odds ratio; CI, confidence interval.
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variable haplotype-based analysis indicated that a haplo-
type, G-C-G, might increase the risk for PD (P = 0.002,
OR = 1.69, 95% CI = 1.06-2.71). The association between
the haplotype and PD remained to be statistically signifi-
cant after Bonferroni correction (P = 0.008, Table 2).
Discussion
PD is the most common neurodegenerative cause of
Parkinsonism, a neurological syndrome characterized by
lesions in the basal ganglia, especially in the substantia
nigra. Mutations in the FBXO7 gene have been identified
to cause Parkinsonian-pyramidal syndrome, an autosomal
recessive Parkinsonism with pyramidal tract signs [9]. We
hypothesize the FBXO42 gene, a paralog of the FBXO7
gene, as a potential candidate gene for PD because
paralogs often retain similar functions [12].
The FBXO42 gene, mapped on chromosome 1p36.13,
contains 11 exons and spans about 105 kb. It encodes a
717-amino-acid protein characterized by an approximately
40-amino-acid F-box motif in its N-terminus and 3 central
kelch repeats downstream of the F-box [19,20]. FBXO42 is
associated with Skp1, Cul1, and Rbx1, and may functionTable 2 Haplotype analysis of rs2273311-rs12069239-rs35196





Pcorr: P-value after Bonferroni correction; OR: odds ratio; CI, confidence interval; stativia assembly of an SCF complex [19]. The SCF complex is
the largest E3 ubiquitin ligase family that promotes the
ubiquitin-dependent degradation of various regulatory
proteins, thus controlling various biological processes, in-
cluding cell cycle progression, gene transcription, signal
transduction, and DNA replication [21]. It has been shown
that FBXO42 is transcriptionally regulated by p53, a tumor
suppressor playing an important role in regulating the cell
cycle and triggering apoptosis [22]. FBOX42 forms an
auto-regulatory negative feedback loop with p53 to
promote ubiquitination and degradation of p53 [19,23]. In
vitro studies have found that inhibition of p53 prevents 6-
hydroxydopamine-induced cell loss [24,25]. In vivo animal
studies suggest that p53 knockout mice or mice pretreated
with a p53 inhibitor are protected from dopaminergic
neuron death in the pars compacta of substantia nigra
[26-28]. Additionally, several studies have also indicated
that p53 is involved in the pathogenesis of PD through
alpha-synuclein, Parkin and DJ-1 [29-31], mutations of
which are known causes for PD phenotype [32].
In the present study, we screened the entire coding
region and intron/exon boundaries of the FBXO42 gene in
316 patients with sporadic PD and 295 gender-, age-, and193 in the FBXO42 gene in PD patients and controls
ls P-value (χ2) Pcorr OR (95% CI)
0.35 (0.88) 0.47 0.72 (0.32-1.62)
0.10 (2.78) 0.19 0.75 (0.47-1.21)
0.002 (9.31) 0.008 1.69 (1.06-2.71)
0.49 (0.47) 0.49 0.92 (0.65-1.30)
stically significant results are marked in bold.
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including a novel one, and three known single nucleotide
variants. The novel variant, c.1407T>C, was detected in
a 78-year-old male patient only. However, this variant
does not change amino acid (p.S469S) or alter splicing,
suggesting the variant is unlikely a pathogenic mutation.
For the three known variants, rs2273311, rs12069239
and rs35196193, there was no significant difference be-
tween patient and control groups for allelic or genotypic
distributions (all P > 0.05). Our results suggest that
none of the four variants identified in the coding region
of the FBXO42 gene seem to play a major genetic role
in the development of PD in Chinese Han population.
Larger studies are needed to confirm our findings.
Single-marker association analysis is sometimes not
sufficient in complex diseases. The haplotype-based link-
age disequilibrium mapping has become a powerful and
robust method for genetic association studies, especially in
search of complex disease-causing genes [33,34]. Our data
indicated that a common haplotype G-C-G (rs2273311-
rs12069239-rs35196193) of the FBXO42 gene conferred a
1.69-fold increased risk for PD. The remaining question
is which haplotype is the key player in the development
of PD.
Conclusions
To our knowledge, this is the first study to evaluate the
FBXO42 gene in a cohort of PD patients and controls.
Data from the present study suggest that the variants in
the coding region of the FBXO42 gene may play little or
no genetic role in PD, but a common haplotype in the
FBXO42 gene may contribute to the susceptibility to PD
in this Chinese Han population. More studies with a larger
sample size from diverse races are warranted to confirm
the results of our findings.
Additional files
Additional file 1: Table S1. Primers for the FBXO42 gene.
Additional file 2: Figure S1. Sequencing analysis of the FBXO42 gene.
(A) The arrow shows the normal sequence. (B) The arrow shows
c.1407T>C (p.S469S) nucleotide substitution.
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